Longwood Capital Partners
Latest statistics and disclosures from Acuta Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are OCUL, PRAX, MRSN, TSHA, RCKT, and represent 40.24% of Acuta Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: OCUL (+$12M), ELVN, APLT, CLDX, AGIO, ORIC, MREO, LYRA, DYN, RARE.
- Started 6 new stock positions in ITCI, LYRA, MREO, RARE, ORIC, AGIO.
- Reduced shares in these 10 stocks: Rayzebio (-$24M), KURA (-$13M), Cymabay Therapeutics (-$12M), EYPT (-$9.8M), PRAX (-$8.4M), APLS, ACLX, ANTX, IRON, FDMT.
- Sold out of its positions in AVXL, ANTX, APLS, ARGX, CNTA, Cymabay Therapeutics, EYPT, FDMT, Rayzebio, SWTX. TYRA, VRNA.
- Acuta Capital Partners was a net seller of stock by $-64M.
- Acuta Capital Partners has $154M in assets under management (AUM), dropping by -13.35%.
- Central Index Key (CIK): 0001582844
Tip: Access up to 7 years of quarterly data
Positions held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 33 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ocular Therapeutix (OCUL) | 15.6 | $24M | +101% | 2.6M | 9.10 |
|
| Praxis Precision Medicines I (PRAX) | 6.4 | $9.9M | -45% | 162k | 61.02 |
|
| Mersana Therapeutics (MRSN) | 6.3 | $9.7M | -8% | 2.2M | 4.48 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 6.2 | $9.6M | -7% | 3.3M | 2.87 |
|
| Rocket Pharmaceuticals (RCKT) | 5.7 | $8.8M | -10% | 327k | 26.94 |
|
| Sarepta Therapeutics (SRPT) | 5.4 | $8.3M | -9% | 64k | 129.46 |
|
| Vaxcyte (PCVX) | 4.7 | $7.2M | -10% | 105k | 68.31 |
|
| Enliven Therapeutics (ELVN) | 4.5 | $7.0M | +219% | 396k | 17.59 |
|
| Tourmaline Bio (TRML) | 3.9 | $6.0M | +12% | 261k | 22.90 |
|
| Applied Therapeutics (APLT) | 3.5 | $5.4M | +50% | 792k | 6.80 |
|
| Dyne Therapeutics (DYN) | 3.4 | $5.2M | +24% | 185k | 28.39 |
|
| Disc Medicine (IRON) | 3.1 | $4.8M | -33% | 77k | 62.26 |
|
| Revolution Medicines (RVMD) | 3.0 | $4.6M | -10% | 144k | 32.23 |
|
| Celldex Therapeutics Com New (CLDX) | 3.0 | $4.6M | +57% | 109k | 41.97 |
|
| Aadi Bioscience (AADI) | 2.8 | $4.3M | 1.8M | 2.34 |
|
|
| Hillevax (HLVX) | 2.7 | $4.2M | -22% | 251k | 16.63 |
|
| Crinetics Pharmaceuticals In (CRNX) | 2.4 | $3.7M | -10% | 78k | 46.81 |
|
| Miragen Therapeutics (VRDN) | 2.3 | $3.5M | -29% | 199k | 17.51 |
|
| Terns Pharmaceuticals (TERN) | 2.0 | $3.1M | -16% | 465k | 6.56 |
|
| Immunovant (IMVT) | 1.9 | $3.0M | -22% | 92k | 32.31 |
|
| Verastem Com New (VSTM) | 1.6 | $2.4M | -10% | 207k | 11.80 |
|
| Arcellx Common Stock (ACLX) | 1.6 | $2.4M | -55% | 35k | 69.55 |
|
| Kura Oncology (KURA) | 1.2 | $1.9M | -87% | 90k | 21.33 |
|
| Insmed Com Par $.01 (INSM) | 1.1 | $1.7M | +109% | 62k | 27.13 |
|
| Agios Pharmaceuticals (AGIO) | 1.0 | $1.6M | NEW | 55k | 29.24 |
|
| Oric Pharmaceuticals (ORIC) | 0.9 | $1.4M | NEW | 104k | 13.75 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.9 | $1.3M | NEW | 398k | 3.30 |
|
| Lyra Therapeutics (LYRA) | 0.7 | $1.1M | NEW | 173k | 6.22 |
|
| Leap Therapeutics Com New (LPTX) | 0.6 | $942k | 354k | 2.66 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 0.6 | $934k | NEW | 20k | 46.69 |
|
| Intra Cellular Therapies (ITCI) | 0.6 | $920k | NEW | 13k | 69.20 |
|
| Cellectar Biosciences Com New (CLRB) | 0.4 | $571k | -69% | 144k | 3.98 |
|
| Nuvation Bio *w Exp 07/07/2027 (NUVB.WS) | 0.0 | $28k | 91k | 0.30 |
|
Past Filings by Acuta Capital Partners
SEC 13F filings are viewable for Acuta Capital Partners going back to 2014
- Acuta Capital Partners 2024 Q1 filed May 15, 2024
- Acuta Capital Partners 2023 Q4 filed Feb. 14, 2024
- Acuta Capital Partners 2023 Q3 filed Nov. 14, 2023
- Acuta Capital Partners 2023 Q2 filed Aug. 14, 2023
- Acuta Capital Partners 2023 Q1 filed May 15, 2023
- Acuta Capital Partners 2022 Q4 filed Feb. 14, 2023
- Acuta Capital Partners 2022 Q3 filed Nov. 14, 2022
- Acuta Capital Partners 2022 Q2 filed Aug. 15, 2022
- Acuta Capital Partners 2022 Q1 filed May 16, 2022
- Acuta Capital Partners 2021 Q4 filed Feb. 14, 2022
- Acuta Capital Partners 2021 Q3 filed Nov. 15, 2021
- Acuta Capital Partners 2021 Q2 filed Aug. 16, 2021
- Acuta Capital Partners 2021 Q1 filed May 17, 2021
- Acuta Capital Partners 2020 Q4 filed Feb. 16, 2021
- Acuta Capital Partners 2020 Q3 filed Nov. 16, 2020
- Acuta Capital Partners 2020 Q2 filed Aug. 14, 2020